The prevalence of tardive dyskinesia after a nine month naturalistic randomized trial comparing olanzapine with conventional treatment for schizophrenia and related disorders

European Archives of Psychiatry and Clinical Neuroscience
Jair de Jesus MariG D Tollefson


To assess the impact of olanzapine versus conventional neuroleptic therapy among subjects with schizophrenia on ratings of tardive dyskinesia (TD). The naturalistic study was conducted in three psychiatric hospitals in Brazil. Patients had a diagnosis of schizophrenia and related disorders (DSMIV) and with a BPRS score>24. Patients were evaluated by means of the PANSS scale for symptomatology (Kay et al. 1986), the Clinical Global Impression, The UKU side effect rating scale (Lingjaerde et al. 1987), and the Tardive Dyskinesia AIMS scale (Guy et al. 1976). Patients were seen by the treating physician routinely while hospitalized and then monthly on an out-patient basis. All scale assessments were repeated after 9 months of discharge. The sample was comprised of 190 patients (99 in the olanzapine and 91 in the standard treatment), with a completion rate of 88.2% for olanzapine and 84.9% for the conventional treatment (p=0.385, n. s.). The mean change from baseline in the PANSS total score favored olanzapine regarding negative symptoms (2.3, 95% C. I. 0.6-4.1, p<0.001); and general psychopathology (4.0, 95% C.I. 0.8-7.2, p<0.02) factors. TD was defined by applying Morgenstern & Glazer (1993) and Schooler & Kane (1982) criteria, o...Continue Reading


Jan 1, 1987·Schizophrenia Bulletin·S R KayL A Opler
Apr 1, 1982·Archives of General Psychiatry·N R Schooler, John M Kane
Feb 1, 1996·Neuropsychopharmacology : Official Publication of the American College of Neuropsychopharmacology·F P BymasterD T Wong
May 1, 1997·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·C M BeasleyJ N Beuzen
Jan 25, 2000·The British Journal of Psychiatry : the Journal of Mental Science·M HotopfG Lewis
Jun 8, 2002·European Psychiatry : the Journal of the Association of European Psychiatrists·Pierre-Michel LlorcaChristophe Lancon


Oct 21, 2009·PLoS Medicine·Mari Jair de JesusGraham Thornicroft
Mar 19, 2009·The Indian Journal of Medical Research·Rajesh Jaco
Nov 6, 2009·Zeitschrift für Kinder- und Jugendpsychiatrie und Psychotherapie·Gerhard RistowLuise Poustka
Feb 7, 2018·The Cochrane Database of Systematic Reviews·Hanna BergmanKarla Soares-Weiser
Jan 17, 2015·The Cochrane Database of Systematic Reviews·Markus DoldStefan Leucht
Apr 6, 2016·The Cochrane Database of Systematic Reviews·Kumar B SahaRashid U Zaman
Sep 8, 2018·World Psychiatry : Official Journal of the World Psychiatric Association (WPA)·Maren CarbonChristoph U Correll
Sep 16, 2006·Journal of Clinical Psychopharmacology·Ana Cristina Chaves, Mary V Seeman
Sep 2, 2011·Drug Safety : an International Journal of Medical Toxicology and Drug Experience·Robert F ReynoldsSybil M Eng

Related Concepts

Population Spatial Distribution
Double-Blind Method
Dyskinesia, Medication-Induced
Etat Marbre
Factor Construct Rating Scales (Fcrs)

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

© 2021 Meta ULC. All rights reserved